Published in Neurology on September 28, 2010
Meditation and Stretching for Post Treatment Lyme Disease Syndrome (LMS) | NCT02344537
Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis | NCT03949296
Meditation and Kundalini Yoga for Persistent Lyme-related Symptoms - an Online Study | NCT04349605
Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19 | NCT04386291
Effects of mindfulness on psychological health: a review of empirical studies. Clin Psychol Rev (2011) 3.51
A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology (2012) 2.46
Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosom Med (2011) 1.93
Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurology (2013) 1.68
Loving-kindness and compassion meditation: potential for psychological interventions. Clin Psychol Rev (2011) 1.56
The mindful brain and emotion regulation in mood disorders. Can J Psychiatry (2012) 1.40
Mindfulness starts with the body: somatosensory attention and top-down modulation of cortical alpha rhythms in mindfulness meditation. Front Hum Neurosci (2013) 1.16
Psychological and neural mechanisms of trait mindfulness in reducing depression vulnerability. Soc Cogn Affect Neurosci (2012) 1.10
Mindfulness based interventions in multiple sclerosis--a systematic review. BMC Neurol (2014) 1.09
Do generic utility measures capture what is important to the quality of life of people with multiple sclerosis? Health Qual Life Outcomes (2013) 1.05
Mindfulness-based interventions for physical conditions: a narrative review evaluating levels of evidence. ISRN Psychiatry (2012) 1.02
Effects of meditation on pain and quality of life in multiple sclerosis and peripheral neuropathy: a pilot study. Int J MS Care (2011) 0.96
Lifestyle factors, demographics and medications associated with depression risk in an international sample of people with multiple sclerosis. BMC Psychiatry (2014) 0.95
Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int (2014) 0.93
Depressive syndromes in neurological disorders. Eur Arch Psychiatry Clin Neurosci (2013) 0.91
Mind-body medicine for multiple sclerosis: a systematic review. Autoimmune Dis (2012) 0.91
Mindfulness-based interventions in multiple sclerosis: beneficial effects of Tai Chi on balance, coordination, fatigue and depression. BMC Neurol (2014) 0.91
Symptom changes in multiple sclerosis following psychological interventions: a systematic review. BMC Neurol (2014) 0.88
Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis recruited via the internet. PLoS One (2015) 0.87
Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol (2012) 0.83
Couples coping with multiple sclerosis: a dyadic perspective on the roles of mindfulness and acceptance. J Behav Med (2012) 0.82
The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial. BMC Neurol (2016) 0.81
Perceived stress in multiple sclerosis: the potential role of mindfulness in health and well-being. J Evid Based Complementary Altern Med (2014) 0.81
Awakening is not a metaphor: the effects of Buddhist meditation practices on basic wakefulness. Ann N Y Acad Sci (2013) 0.81
Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers. Brain Disord Ther (2014) 0.81
The effects of a mindfulness-based lifestyle program for adults with Parkinson's disease: a mixed methods, wait list controlled randomised control study. BMC Neurol (2016) 0.80
Facilitating medication adherence in patients with multiple sclerosis. Int J MS Care (2013) 0.79
The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA J (2016) 0.79
The Effect of Biofeedback as a Psychological Intervention in Multiple Sclerosis: A Randomized Controlled Study. Int J MS Care (2015) 0.79
The effect of physical activity and motivation on function in ankylosing spondylitis: a cohort study. Semin Arthritis Rheum (2013) 0.79
Meditation as an adjunct to the management of multiple sclerosis. Neurol Res Int (2014) 0.78
Healing the mind: meditation and multiple sclerosis. Neurology (2010) 0.78
Managing psychological stress in the multiple sclerosis medical visit: Patient perspectives and unmet needs. J Health Psychol (2014) 0.78
Biological outcome measurements for behavioral interventions in multiple sclerosis. Ther Adv Neurol Disord (2011) 0.78
A telemedicine meditation intervention for people with multiple sclerosis and their caregivers: study protocol for a randomized controlled trial. Trials (2016) 0.78
Effect of Mindfulness-Based Stress Reduction on Anxiety, Depression and Stress in Women With Multiple Sclerosis. Nurs Midwifery Stud (2015) 0.76
Yoga as a method of symptom management in multiple sclerosis. Front Neurosci (2015) 0.76
Can meditation influence quality of life, depression, and disease outcome in multiple sclerosis? Findings from a large international web-based study. Behav Neurol (2014) 0.76
Mindfulness for Motor and Nonmotor Dysfunctions in Parkinson's Disease. Parkinsons Dis (2016) 0.76
Clinical Utility of Mindfulness Training in the Treatment of Fatigue After Stroke, Traumatic Brain Injury and Multiple Sclerosis: A Systematic Literature Review and Meta-analysis. Front Psychol (2016) 0.76
The Effect of Group Mindfulness-based Stress Reduction and Consciousness Yoga Program on Quality of Life and Fatigue Severity in Patients with MS. J Caring Sci (2016) 0.75
Mindfulness-based stress reduction for people with multiple sclerosis - a feasibility randomised controlled trial. BMC Neurol (2017) 0.75
Patient education for people with multiple sclerosis-associated fatigue: A systematic review. PLoS One (2017) 0.75
Teaching mindfulness meditation to adults with severe speech and physical impairments: An exploratory study. Neuropsychol Rehabil (2014) 0.75
A mindfulness-based program for improving quality of life among hematopoietic stem cell transplantation survivors: feasibility and preliminary findings. Support Care Cancer (2014) 0.75
Applying theories and interventions from behavioral medicine to understand and reduce visual field variability in patients with vision loss. Med Hypotheses (2014) 0.75
The effect of mindfulness training prior to total joint arthroplasty on post-operative pain and physical function: study protocol for a randomised controlled trial. Trials (2014) 0.75
The survey of mindfulness in multiple sclerosis patients and its association with attachment style. J Educ Health Promot (2017) 0.75
The Effectiveness of Mindfulness-Based Stress Reduction on Psychological Distress and Cognitive Functioning in Patients with Multiple Sclerosis: a Pilot Study. Mindfulness (N Y) (2017) 0.75
Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol (2017) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Mindfulness-based stress reduction and health benefits. A meta-analysis. J Psychosom Res (2004) 8.53
Mindfulness training as an intervention for fibromyalgia: evidence of postintervention and 3-year follow-up benefits in well-being. Psychother Psychosom (2007) 2.46
Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry (2005) 2.35
Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol (2002) 2.34
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry (1998) 1.84
Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer (2005) 1.80
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler (2002) 1.80
Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol (2001) 1.66
Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes (2008) 1.56
A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med (2008) 1.50
Health-related quality of life as a predictor of pediatric healthcare costs: a two-year prospective cohort analysis. Health Qual Life Outcomes (2004) 1.48
Health status and quality of life of people with multiple sclerosis. Disabil Rehabil (2001) 1.31
Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med (2001) 1.26
Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler (2001) 1.22
Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Qual Life Res (2005) 1.14
Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur J Neurol (2009) 1.05
Brain-immune communication psychoneuroimmunology of multiple sclerosis. Mult Scler (2007) 1.05
Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis. Mult Scler (2009) 1.03
A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci (2003) 1.03
Effects of psychological group therapy in patients with multiple sclerosis. Acta Neurol Scand (2003) 1.02
Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes (2006) 1.01
Reduction in disability in a randomized controlled trial of telephone-administered cognitive-behavioral therapy. Health Psychol (2007) 1.00
Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment. Mult Scler (2002) 1.00
The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler (1999) 0.99
Disability rating scales in multiple sclerosis. Ann N Y Acad Sci (1984) 0.96
Redefining functionality and treatment efficacy in multiple sclerosis. Neurology (2009) 0.95
Group psychotherapy: benefits in multiple sclerosis. Arch Phys Med Rehabil (1985) 0.90
Responsiveness of patient-based and external rating scales in multiple sclerosis: head-to-head comparison in three clinical settings. J Neurol Sci (2009) 0.89
Fatigue, depression and progression in multiple sclerosis. Mult Scler (2008) 0.88
[Quality of life in patients with remitting-relapsing multiple sclerosis in Germany]. Nervenarzt (2003) 0.82
Comorbidity measures for use with administrative data. Med Care (1998) 46.67
The metagenomics RAST server - a public resource for the automatic phylogenetic and functional analysis of metagenomes. BMC Bioinformatics (2008) 29.20
The use of gene clusters to infer functional coupling. Proc Natl Acad Sci U S A (1999) 16.35
Experimental determination and system level analysis of essential genes in Escherichia coli MG1655. J Bacteriol (2003) 7.32
WIT: integrated system for high-throughput genome sequence analysis and metabolic reconstruction. Nucleic Acids Res (2000) 7.10
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Modular structure of a chicken lysozyme silencer: involvement of an unusual thyroid hormone receptor binding site. Cell (1990) 4.13
Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA (1976) 3.82
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Use of contiguity on the chromosome to predict functional coupling. In Silico Biol (1999) 3.25
Ebola virus outbreak among wild chimpanzees living in a rain forest of Côte d'Ivoire. J Infect Dis (1999) 2.34
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07
Activity of two different silencer elements of the chicken lysozyme gene can be compensated by enhancer elements. EMBO J (1987) 2.07
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology (2010) 2.04
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A (1990) 1.93
Self glycolipids as T-cell autoantigens. Eur J Immunol (1999) 1.93
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Patterns of atrioventricular conduction in the human heart. Circ Res (1970) 1.87
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology (2011) 1.83
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
PatSearch: a pattern matcher software that finds functional elements in nucleotide and protein sequences and assesses their statistical significance. Bioinformatics (2000) 1.76
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology (2011) 1.75
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity (2000) 1.72
[Lesions of the brachial plexus occurring after radiotherapy for cancer of the breast]. Schweiz Med Wochenschr (1971) 1.66
The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler (2009) 1.65
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler (2009) 1.65
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology (1990) 1.61
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev (2001) 1.59
Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 1.57
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology (1997) 1.55
Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology (2003) 1.54
Lysozyme gene activity in chicken macrophages is controlled by positive and negative regulatory elements. Nucleic Acids Res (1987) 1.54
Pht2;1 encodes a low-affinity phosphate transporter from Arabidopsis. Plant Cell (1999) 1.54
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler (2011) 1.51
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
The antiarrhythmic actions of carbamazepine (Tegretol). J Pharmacol Exp Ther (1970) 1.45
Dermatology opinions via intranet could reduce waiting times. BMJ (1999) 1.40
Questionnaire assessment of patients' attitudes and beliefs about asthma. Fam Pract (1986) 1.37
A simple technique for production of chronic complete heart block in dogs. J Appl Physiol (1968) 1.36
Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med (1997) 1.36
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29
Dyschromatosis universalis hereditaria. Clin Exp Dermatol (2002) 1.29
Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler (2003) 1.28
Hermansky-Pudlak syndrome type 3 in Ashkenazi Jews and other non-Puerto Rican patients with hypopigmentation and platelet storage-pool deficiency. Am J Hum Genet (2001) 1.28
Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol (2009) 1.27
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology (2011) 1.25
MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler (2006) 1.25
Mechanisms of T cell-induced glomerular injury in anti-glomerular basement membrane (GBM) glomerulonephritis in rats. Clin Exp Immunol (1997) 1.25
Biochemical and biological characterization of a human Rac2 GTPase mutant associated with phagocytic immunodeficiency. J Biol Chem (2001) 1.23
Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology (1995) 1.19
Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand (2009) 1.17
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain (1998) 1.15
HLA-DQ beta-chain polymorphism in HLA-DR4 haplotypes associated with rheumatoid arthritis. Lancet (1987) 1.13
BMP-6 is an autocrine stimulator of chondrocyte differentiation. J Bone Miner Res (1999) 1.11
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol (2002) 1.10
The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis. Mult Scler (2007) 1.08
Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res (2000) 1.08
A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility. Genes Immun (2011) 1.08
Predictors of relapse rate in MS clinical trials. Neurology (2005) 1.06
MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol (2009) 1.05
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler (2013) 1.05
Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control. Mult Scler (2007) 1.05
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology (2012) 1.05
Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. Exp Brain Res (2008) 1.04
Anterior pituitary axis hormones and outcome in acute ischaemic stroke. J Intern Med (2011) 1.03
Anaesthetic management of children with Joubert syndrome. Paediatr Anaesth (1997) 1.03
Acute rejection of vascular heart allografts by perforin-deficient mice. Eur J Immunol (1995) 1.02
Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol (2000) 1.02
Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology (2005) 1.01
A study of atrioventricular conduction in man using premature atrial stimulation and His bundle recordings. Circulation (1969) 1.01
Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology (2001) 1.01
Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology (2006) 1.01
Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation. Am J Transplant (2011) 1.00
Magnetic resonance imaging and early diagnosis of multiple sclerosis. Lancet (1988) 0.99
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. Mult Scler (2011) 0.99
HLA antigens and toxic reactions to sodium aurothiomalate in patients with rheumatoid arthritis. J Rheumatol (1984) 0.99
Fine needle aspiration cytology (FNAC) of nerves in leprosy. Lepr Rev (2001) 0.99
BMP signaling stimulates chondrocyte maturation and the expression of Indian hedgehog. J Orthop Res (2001) 0.98
Effects of glucagon on atrioventricular conduction and ventricular automaticity in dogs. Circ Res (1969) 0.98
[Facial myokymia caused by pontine lesions and central fever in multiple sclerosis--case report]. Schweiz Rundsch Med Prax (1991) 0.98
Reproducibility of fMRI in the clinical setting: implications for trial designs. Neuroimage (2008) 0.98
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology (2010) 0.97
The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain (2001) 0.97
Phenomenon of the gap in atrioventricular conduction in the human heart. Circ Res (1970) 0.97
Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. J Magn Reson Imaging (2000) 0.97
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler (2013) 0.97
Outpatient mastectomy: clinical, payer, and geographic influences. Health Serv Res (2001) 0.97
PTHrP expression in chondrocytes, regulation by TGF-beta, and interactions between epiphyseal and growth plate chondrocytes. Exp Cell Res (2000) 0.97